Odyssean LLC Invests $897,000 in Tempus AI, Inc. $TEM

Odyssean LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the second quarter, Holdings Channel reports. The institutional investor bought 15,476 shares of the company’s stock, valued at approximately $897,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEM. Victory Capital Management Inc. boosted its stake in Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the period. Truist Financial Corp increased its stake in Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after purchasing an additional 194 shares during the period. SeaCrest Wealth Management LLC increased its stake in Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after purchasing an additional 229 shares during the period. Geneos Wealth Management Inc. raised its holdings in shares of Tempus AI by 29.4% in the fourth quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock valued at $65,000 after buying an additional 250 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Tempus AI by 64.5% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company’s stock valued at $53,000 after buying an additional 256 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Down 0.4%

NASDAQ TEM opened at $68.48 on Thursday. The stock has a market capitalization of $12.36 billion, a P/E ratio of -47.56 and a beta of 3.58. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The firm has a 50-day moving average price of $53.97 and a 200 day moving average price of $51.60. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the company earned ($0.22) EPS. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. Equities research analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current year.

Insiders Place Their Bets

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the sale, the chief executive officer owned 200,000 shares of the company’s stock, valued at approximately $8,412,000. This trade represents a 55.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 26,313 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer owned 106,024 shares in the company, valued at $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 791,238 shares of company stock worth $39,653,732. Insiders own 24.26% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Wolfe Research started coverage on Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. HC Wainwright reduced their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. BTIG Research increased their price objective on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Guggenheim lifted their target price on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Tempus AI presently has an average rating of “Hold” and an average target price of $65.69.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.